BusinessCascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal CancerBy Nasdaq OMXSep 27, 2017, 11:00 AM UTC
BusinessTucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 CongressBy Nasdaq OMXSep 11, 2017, 10:00 AM UTC
BusinessCascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 CongressBy Nasdaq OMXAug 28, 2017, 12:30 PM UTC
BusinessCascadian Therapeutics Reports Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 8, 2017, 8:01 PM UTC
BusinessCascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in EuropeBy Nasdaq OMXJul 11, 2017, 12:01 PM UTC
BusinessCascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain MetastasesBy Nasdaq OMXJun 8, 2017, 12:01 PM UTC
BusinessCascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ETBy Nasdaq OMXMay 9, 2017, 11:01 AM UTC
BusinessCascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ETBy Nasdaq OMXMay 9, 2017, 11:01 AM UTC
